| Name |
|---|
|
Fund for R&D in Neglected Diseases (FRIND) Championed by Novartis, the Fund for Research in Neglected Disease (FRIND) would apply the portfolio management techniques used by private pharmaceutical firms for their mainstream drug pipelines for research in neglected disease. The proponents of FRIND argue that many individual research projects, some of which may duplicate efforts, currently compete for an inadequate pool of donor funding. FRIND proposes that all available funding be pooled and then allocated by a board that represents developing countries, major funders, OECD countries and other international health stakeholders. |
|
Industry R&D Facilitation Fund (IRFF) The Industry R&D Facilitation Fund (IRFF) is a pooled funding mechanism that would provide secure funding to select Product Development Partnerships (PDPs). The PDPs would receive fixed shares from a pooled fund and must use the funding to expand contracts with the private sector. The funding intends to be flexible, allowing the PDPs to rely on their own expertise in managing their research portfolios. Having a source of predictable funding may also encourage biotechs and pharmaceutical companies to work with PDPs as there is a lesser risk of funding fluctuation. |
|
New Global Fund for R&D A Global Fund for R&D (comparable to the Global Fund to Fight AIDS, Tuberculosis and Malaria) could absorb contributions for global health research from governments, levies and voluntary contributions. The Fund could set research priorities and channel funding to critical areas. The Fund would likely include Type I, II and III diseases and stress capacity-building in developing countries. Having a unified international presence for global health R&D may garner more interest in R&D from the public and various governments. |
|
Product Development Partnership Financing Facility (PDPFF) The Product Development Partnership Financing Facility (PDPFF) intends to leverage the future social value of global health products for immediate funding. The facility would provide predictable funding to a group of PDPs though bond financing, encouraging them to produce technologies viable in the global health market. Royalties from future rich-world sales (and from a possible premium on donor-backed sales in low-income countries) could contribute to repaying the bonds. |
|
New Innovation Fund The New Innovation Fund aims to benefit local R&D in the pharmaceutical sector and to improve market competitiveness. This fund would be a national level fund for R&D focusing on orphan and neglected diseases that would require all beneficiaries to license their technologies to generic manufacturers. The proponents pose two possibilities—the first offers innovators less project support and a two year monopoly period and the second offers a much higher level of financing but no period of market exclusivity. |